Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Clinical trial NCT05943496 · RECRUITING
Trial details
- NCT number
- NCT05943496
- Sponsor
- OHSU Knight Cancer Institute
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-02
- Primary completion
- 2027-01-01
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.